Clinical trial NCT02466165: Multiple Sclerosis: Associated Cardiometabolic Risks and Impact of Exercise Therapy
Official title: Multiple Sclerosis: Associated Cardiometabolic Risks and Impact of Exercise Therapy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Multiple Sclerosis
Healthy Controls
Keywords: cardiometabolic risk
physical exercise
Lead sponsor: Hasselt University
Sponsor class: OTHER
First posted: 2015-06-09
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Multiple Sclerosis (MS) is the most common chronic inflammatory neurological disorder in young adults. Due to heterogeneous symptoms, MS patients are often more inactive than healthy controls, resulting in an inactivity related physiological profile. In healthy people, physical inactivity can contribute to the development of an increased cardiometabolic risk state including the combined presence of cardiovascular risk factors (increased cholesterol, elevated blood pressure, body fat, glucose intolerance/insulin resistance, inflammation and reduced heart function/autonomic control). In other populations, these secondary health complications can be, in part, reduced by physical exercise, which is often used as the primary treatment strategy. Since the impact of exercise on cardiovascular risk factors in MS is unknown the present project first aims to explore this in a pilot trial and a controlled research setting (during 12 weeks). A better understanding of the above described risk factors and underlying physiological mechanisms will reduce the incidence of preventable comorbidities in MS and will further improve the multidisciplinary treatment of MS patients and MS rehabilitation in particular. Interestingly, the investigators already reported an elevated prevalence of impaired glucose tolerance in MS, but it is not clear whether the cardiometabolic state in MS is also impaired. Therefore, in a second part, the researchers will explore whether MS patients present a higher risk to develop cardiovascular diseases, as measured by the assessment of various cardiovascular risk factors, compared to healthy controls.

Detailed description: In a first part, various cardiovascular risk factors will be determined in a group of MS patients (n=\~16). These patients will be enrolled in a pilot trail, investigating the feasability and impact of a high intense interval exercise intervention (12 weeks high intensity interval training). After 12 weeks, baseline cardiovascular risk measurements will be repeated to determine the impact of high intensity interval training on these risk factors in MS.

In a second part, these cardiovascular risk factors in a larger group of MS patients (n=\~50) will be compared to healthy controls (n=\~25), in order to determine whether MS patients show an increased prevalence of cardiovascular risk factors, and thus an elevated risk to develop cardiovascular diseases.

In total, a group of 80 subjects (MS patients and HC) will be investigated throughout this study, with only MS patients participating in the pilot trial/exercise intervention.

Measurements of cardiovascular risk factors will include:

* body composition (DEXA)
* blood pressure and heart rate (Omron M4-I)
* whole body glucose disposal (oral glucose tolerance test)
* blood analysis: insulin, total cholesterol, high- density lipoprotein, low-density lipoprotein, plasma triglycerides, C-reactive protein and glycosylated haemoglobin.

Furthermore, a maximal exercise test (determination maximal heart rate, workload, lactate concentrations, etc) and an isometric/isokinetic strength test will be performed to determine the impact of the rehabilitation program in MS patients.

Eligibility criteria: Inclusion Criteria:

Healthy controls:

* male/female
* 18 years
* written informed consent (Declaration of Helsinki and ethical committee guidelines)

MS patients:

* cfr healthy controls criteria, in addition:
* Diagnosed MS according to the McDonald criteria
* Expanded Disability Status Scale (EDSS) between 1 and 7
* Being available for the complete study course

Exclusion Criteria:

* other disorders
* pregnancy
* participation in another study
* MS exacerbation 6 months prior to the start.
* for the MS patients: contra-indication to perform physical exercise

Primary outcomes:
measure: dyslipidemia, as determined by the analysis of blood samples
timeFrame: change from baseline up to 12 weeks
measure: hypertension / blood pressure as determined by supine blood pressure measures
timeFrame: change from baseline up to 12 weeks
measure: body fat as determined by DEXA scan
timeFrame: change from baseline up to 12 weeks
measure: glucose tolerance / insulin resistance as determined by oral glucose tolerance test
timeFrame: change from baseline up to 12 weeks
measure: inflammation as determined by analysis of blood samples
timeFrame: change from baseline up to 12 weeks
Secondary outcomes:
measure: muscle strength of knee extensor/flexor and elbow extensor/flexor as determined by Biodex
timeFrame: change from baseline up to 12 weeks
measure: aerobic capacity as determined by a maximal endurance test on the bike
timeFrame: change from baseline up to 12 weeks
measure: blood lactate concentrations during exercise as determined by a maximal endurance test on the bike
timeFrame: change from baseline up to 12 weeks
measure: heart function
timeFrame: change from baseline up to 12 weeks
Other outcomes:
Locations:
city: Diepenbeek
country: Belgium
facility: REVAL
city: Hasselt
country: Belgium
facility: Jessa hospital
Study officials:
affiliation: Hasselt University, REVAL/BIOMED
name: Bert O Eijnde, Ph.D.
role: STUDY_CHAIR
References: